Noya

Hangzhou Noya Medtech Co., Ltd. was founded in 2017, incubated by D&N Medical, and is committed to providing new treatment solutions for heart failure patients worldwide. The company's main product, the NoYA(TM) Radiofrequency Atrial Shunt System, is the world’s first non-implantable device for atrial shunting, ushering in a non-implantable era for cardiac catheter-based treatments and addressing the unmet need in heart failure, particularly Heart Failure with Preserved Ejection Fraction (HFpEF). As of December 2020, Noya has filed 83 patent applications and obtained 17 authorized patents.